0000000000141002
AUTHOR
Giacomin A.
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.
Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …
Hematological Malignancies in the Elderly: The Epidemiological Perspective
In the more developed countries the total number of new cases with a hematological tumour was 415,433 for all ages, whilst 188,654 occurred in people aged 70 or more years, representing the 45 % of total cases, equally divided into two sexes. The most these malignancies is closely linked to age and incidence rates increased exponentially after 50 years of age. Aetiology of hematological tumours is largely unknown. However the basic causal mechanism could be a decline in adaptive immunity, strongly related with individual age. In addition to such immunodeficiency, some specific risk factors have been found: viral infections, overweight and obesity (particularly for non-Hodgkin’s lymphomas - …